SS-31 Peptide Research: 7 Essential Findings on Cardiolipin and Mitochondrial Function
Exploring elamipretide, inner mitochondrial membrane structure, cellular energy production, oxidative stress and the clinical evidence behind cardiolipin-targeted research.
SS-31 peptide research examines how a synthetic, mitochondria-targeted tetrapeptide interacts with cardiolipin, an unusual phospholipid concentrated in the inner mitochondrial membrane. Also known as elamipretide, SS-31 has been studied for its effects on membrane organisation, respiratory-chain function, cellular energy metabolism and responses to mitochondrial stress. SS-31 peptide research
Unlike many experimental peptides that act through cell-surface receptors, SS-31 is primarily associated with interactions at mitochondrial membranes. Its combination of positively charged and aromatic amino acid residues allows it to associate with lipid environments, particularly those containing cardiolipin.
This interaction has been investigated through membrane biophysics, cell experiments, animal models and human clinical studies.
SS-31 is also unusual among peptides commonly discussed in research catalogues because a pharmaceutical formulation of elamipretide has received regulatory approval for a specific rare disease.
On 19 September 2025, the United States Food and Drug Administration granted accelerated approval to Forzinity (elamipretide) to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
The approval was based on a defined pharmaceutical product and a particular body of clinical evidence. It does not mean that independently supplied SS-31 research materials are approved medicines, or that the peptide has established benefits for healthy individuals, athletic performance or general ageing.
This article examines seven major findings and distinguishes established molecular interactions from proposed mechanisms and clinical conclusions. SS-31 peptide research
1. What Is SS-31? Structure, Sequence and Scientific Identity
SS-31 belongs to a family of synthetic peptides developed by Hazel Szeto and colleagues, commonly known as Szeto–Schiller peptides. SS-31 peptide research
These compounds were designed to interact with cellular membranes and have been extensively investigated in mitochondrial research.
SS-31 Is a Tetrapeptide
A tetrapeptide contains four amino acid residues.
SS-31 is commonly represented by the sequence:
D-Arg–Dmt–Lys–Phe–NH₂
The residues are:
- D-arginine
- 2′,6′-dimethyltyrosine, abbreviated Dmt
- Lysine
- Phenylalanine, with a C-terminal amide
The D-arginine residue and modified tyrosine are important structural features.
SS-31 is not simply a naturally occurring four-amino-acid fragment. SS-31 peptide research
SS-31 Molecular Specifications
| Property | Scientific description |
|---|---|
| Research designation | SS-31 |
| Pharmaceutical name | Elamipretide |
| Other historical designation | Bendavia |
| Peptide class | Synthetic mitochondria-targeted tetrapeptide |
| Sequence | D-Arg–Dmt–Lys–Phe–NH₂ |
| Amino acid residues | 4 |
| Approximate molecular mass | 639.8 Da for the unmodified free peptide |
| Principal molecular interaction | Association with cardiolipin-containing mitochondrial membranes |
| Main research fields | Membrane biophysics, oxidative phosphorylation, mitochondrial stress and Barth syndrome |
| Approved US pharmaceutical product | Forzinity (elamipretide), for a restricted Barth syndrome indication |
Molecular mass and chemical specifications must be interpreted in relation to the exact supplied form, including counterions and formulation components. SS-31 peptide research
Why Does the Sequence Matter?
SS-31 combines positively charged groups with aromatic residues.
This arrangement contributes to its interaction with negatively charged membrane surfaces.
The peptide’s physical properties are therefore central to its proposed mechanism.
Is SS-31 the Same as Elamipretide?
In scientific literature, SS-31 and elamipretide generally refer to the same active peptide.
However, chemical identity does not establish pharmaceutical equivalence.
An independently supplied research material is not automatically equivalent to an approved drug product in manufacturing quality, formulation, sterility, stability or regulatory status.
Is SS-31 Naturally Produced in Humans?
SS-31 is a synthetic peptide, not a known endogenous mitochondrial-derived peptide.
This distinguishes it from compounds such as MOTS-c, whose coding sequence originates in mitochondrial DNA.
2. SS-31 and Cardiolipin: The Central Molecular Interaction
The defining feature of SS-31 research is its interaction with cardiolipin. SS-31 peptide research
Cardiolipin is a distinctive phospholipid associated predominantly with the inner mitochondrial membrane. SS-31 peptide research
What Makes Cardiolipin Different?
Cardiolipin has a structure containing four fatty-acid chains and two phosphate-containing groups.
Its unusual molecular architecture contributes to the physical organisation of mitochondrial membranes.
Cardiolipin also interacts with proteins involved in mitochondrial energy production. SS-31 peptide research
Why Is Cardiolipin Important?
Cardiolipin contributes to the stability and organisation of membrane proteins and respiratory-chain assemblies.
It is particularly relevant to mitochondrial cristae, the folds of the inner mitochondrial membrane. SS-31 peptide research
How Does SS-31 Interact With Cardiolipin?
Experimental studies support interactions involving electrostatic and hydrophobic forces.
The positively charged groups of SS-31 can interact with negatively charged membrane components, while its aromatic residues contribute to interactions within the lipid environment.
Is Cardiolipin the Only Relevant Interaction?
No.
Although cardiolipin is central to the established research literature, studies also show that SS-31 can influence membrane surface properties more broadly. SS-31 peptide research
The peptide’s behaviour depends on lipid composition and membrane charge. SS-31 peptide research
The 2020 Membrane Biophysics Study
Mitchell and colleagues investigated SS-31 interactions with model and mitochondrial membranes.
The researchers found that SS-31 partitioned into the membrane interface and changed lipid packing and surface electrostatics.
The effects were influenced by membrane charge.
Why Surface Electrostatics Matter
Electrical charge at a membrane surface can influence the distribution and behaviour of ions and proteins.
Changes in these properties may affect biological processes without requiring direct activation of a conventional receptor.
What About Calcium?
The 2020 study reported that SS-31 could alter calcium distribution at membrane interfaces in experimental systems.
This provided another potential mechanism connecting membrane interactions with mitochondrial stress responses. SS-31 peptide research
What Can Be Concluded?
SS-31 has experimentally supported interactions with cardiolipin-containing membranes.
However, the precise contributions of lipid binding, membrane electrostatics and protein interactions may differ between experimental systems.
3. SS-31 Research and Mitochondrial Cristae Organisation
Mitochondrial cristae are folds of the inner mitochondrial membrane.
They provide a specialised environment for the protein complexes involved in oxidative phosphorylation.
What Is the Inner Mitochondrial Membrane?
Mitochondria have an outer membrane and an inner membrane. SS-31 peptide research
The inner membrane contains components of the electron transport chain and ATP-producing machinery.
Its organisation is important for mitochondrial function.
Why Cristae Structure Matters
Cristae shape and organisation influence the arrangement of respiratory proteins.
Changes in membrane architecture can affect the local environment in which energy-related reactions occur.
Cardiolipin and Cristae
Cardiolipin contributes to membrane curvature and interactions among respiratory-chain proteins.
Alterations in cardiolipin composition can be associated with changes in mitochondrial structure.
What Has SS-31 Research Reported?
Preclinical studies have described SS-31-associated changes in mitochondrial membrane organisation and selected measurements of cristae structure.
These observations support investigating whether interactions with cardiolipin can influence mitochondrial architecture.
Does SS-31 Repair Every Damaged Mitochondrion?
No.
A change in cristae organisation in one experimental model does not establish universal mitochondrial repair.
Different forms of mitochondrial dysfunction arise from different genetic, biochemical and environmental causes. SS-31 peptide research
How Do Researchers Measure Cristae?
Electron microscopy can provide structural information about mitochondrial membranes.
Other techniques can assess membrane-associated proteins, lipid composition and mitochondrial function.
Why Multiple Measurements Are Needed
A structural change does not necessarily correspond to an identical functional change.
Researchers should distinguish between membrane appearance and direct measurements of respiratory activity or ATP production.
4. SS-31, Cytochrome c and Oxidative Stress
Cytochrome c is a protein involved in electron transport within mitochondria.
Its behaviour is influenced by interactions with membrane lipids, including cardiolipin.
The Normal Role of Cytochrome c
Cytochrome c transfers electrons between respiratory-chain complexes.
This function contributes to the electrochemical processes that support ATP production. SS-31 peptide research
Cardiolipin and Cytochrome c
Under certain conditions, interactions between cardiolipin and cytochrome c can change the protein’s behaviour.
Experimental studies have examined the development of peroxidase-like activity in these settings.
What Is Peroxidase Activity?
Peroxidase activity involves reactions associated with peroxide-containing molecules.
These reactions can influence lipid oxidation and other chemical processes.
SS-31 and Cytochrome c
Early mechanistic research proposed that SS-31 could influence cardiolipin–cytochrome c interactions, potentially limiting certain peroxidase-associated processes while preserving electron-transfer function.
This remains an important hypothesis in the literature. SS-31 peptide research
Does SS-31 Directly Eliminate Reactive Oxygen Species?
It should not be described simply as a universal reactive oxygen species scavenger.
Its effects may involve membrane interactions and changes in the conditions that contribute to oxidative stress.
What Are Reactive Oxygen Species?
Reactive oxygen species are chemically reactive oxygen-containing molecules.
They can participate in normal cellular signalling.
Excessive or poorly regulated production may contribute to cellular damage.
Why Reducing ROS Is Not Always Beneficial
Reactive oxygen species also have physiological signalling roles.
A decrease in a particular oxidative stress marker does not automatically establish an improved health outcome.
Research Interpretation
Preclinical findings support investigating SS-31 in relation to cardiolipin oxidation, cytochrome c behaviour and mitochondrial oxidative stress.
The significance of these mechanisms must be evaluated separately in each disease or experimental context.
5. SS-31 and Mitochondrial Energy Production
Mitochondria produce much of the ATP used by many human cells. SS-31 peptide research
SS-31 has been studied for its possible effects on the efficiency and organisation of this process.
What Is Oxidative Phosphorylation?
Oxidative phosphorylation is a process in which mitochondrial respiratory-chain activity helps establish an electrochemical gradient used to produce ATP.
The process depends on the coordinated function of membrane-associated proteins.
Respiratory-Chain Complexes
Several large protein complexes participate in electron transport.
Their arrangement and interactions with surrounding lipids can influence mitochondrial function.
Cardiolipin and Protein Organisation
Cardiolipin interacts with numerous mitochondrial proteins.
Changes in cardiolipin composition may alter the behaviour of respiratory-chain assemblies.
What Has SS-31 Research Found?
Preclinical studies have reported changes in mitochondrial respiration, ATP-associated measurements and related functional outcomes following SS-31 exposure.
The findings vary by model. SS-31 peptide research
The 2020 Protein Interaction Study
A study using chemical cross-linking and mass spectrometry identified mitochondrial proteins associated with SS-31.
Several identified proteins were involved in oxidative phosphorylation or related metabolic pathways.
The findings expanded the proposed interaction landscape beyond a simple one-peptide–one-lipid model.
Does Protein Association Prove Direct Functional Activation?
No.
A protein detected through a cross-linking experiment is not necessarily directly activated by the compound.
The interaction may depend on proximity, membrane organisation or other factors.
Measuring Oxygen Consumption
Researchers frequently measure oxygen consumption as one indicator of mitochondrial respiratory activity.
However, oxygen consumption alone does not establish ATP-production efficiency.
Why ATP Measurements Matter
ATP levels are influenced by production, consumption and other cellular processes.
An increase in cellular ATP does not necessarily demonstrate that a compound directly activates the electron transport chain.
Appropriate Interpretation
SS-31 provides an experimental tool for examining how membrane-associated processes influence mitochondrial bioenergetics.
The available data do not establish general energy-enhancing benefits in healthy humans. SS-31 peptide research
6. SS-31 Clinical Research and the 2025 Barth Syndrome Approval
SS-31 has progressed beyond preclinical investigation into human clinical development.
Its most important regulatory milestone occurred in September 2025. SS-31 peptide research
What Is Barth Syndrome?
Barth syndrome is a rare genetic disorder associated with pathogenic variants in the TAZ gene.
TAZ encodes tafazzin, a protein involved in cardiolipin remodelling.
Disruption of this process can affect mitochondrial membrane composition and function.
Why Was Elamipretide Studied?
Because cardiolipin abnormalities are central to Barth syndrome, a compound that interacts with cardiolipin offered a scientifically plausible therapeutic approach.
The Clinical Development Programme
Elamipretide was evaluated in a small randomised, double-blind, placebo-controlled crossover study involving patients with Barth syndrome. SS-31 peptide research
An open-label extension provided additional information over a longer period.
What Happened in the Controlled Trial?
The controlled trial did not demonstrate statistically significant improvements in its principal six-minute walk and fatigue outcomes.
This is an important limitation.
What Supported the Accelerated Approval?
The FDA considered the broader evidence package, including longer-term extension findings and muscle-strength measurements.
The approval was granted through the accelerated approval pathway, which requires additional evidence to confirm clinical benefit.
What Exactly Did the FDA Approve?
On 19 September 2025, the FDA granted accelerated approval to Forzinity (elamipretide) for improving muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
This is a specific indication, not approval for general mitochondrial health.
Does This Mean SS-31 Is Proven for All Mitochondrial Disorders?
No.
Clinical findings in Barth syndrome cannot automatically be applied to mitochondrial myopathies, cardiovascular disease, neurological disorders or healthy individuals.
Why the Approval Matters Scientifically
It represents an important milestone for therapies targeting mitochondrial membrane biology.
It also demonstrates the importance of distinguishing a promising mechanism from the evidence required for a defined clinical indication. SS-31 peptide research
Is Research-Grade SS-31 the Same as Forzinity?
No.
A research peptide and an approved pharmaceutical product may share an active molecular structure while differing in manufacturing controls, formulation, specifications, sterility assurance and regulatory oversight.
An approved elamipretide medicine must not be equated with independently supplied research materials.
7. SS-31 Research Limitations, Ageing Claims and Future Directions
SS-31 has been examined in several disease-related experimental models.
These include research involving cardiac, skeletal muscle, kidney and neurological processes.
However, the strength of the evidence varies substantially by application.
SS-31 and Ageing Research
Ageing-related changes in mitochondrial function have motivated studies involving SS-31.
Some animal experiments have reported changes in mitochondrial measurements or selected functional outcomes.
Does SS-31 Reverse Human Ageing?
No reliable clinical evidence establishes SS-31 as a treatment that reverses normal human ageing.
SS-31 and Exercise Performance
Mitochondrial energy production is relevant to exercise physiology. SS-31 peptide research
However, this relationship does not establish that SS-31 improves athletic performance in healthy people.
SS-31 and Cardiovascular Research
Experimental studies have examined SS-31 in models of cardiac stress and mitochondrial dysfunction.
Findings from these models cannot be treated as proof of clinical benefit in human cardiovascular disease.
SS-31 and Kidney Research
Preclinical investigations have examined mitochondrial responses in kidney-related injury models.
The relevance of these findings to human kidney disease requires disease-specific clinical evidence.
SS-31 and Neurological Research
Mitochondrial function is important in nervous-system biology.
Nevertheless, general mitochondrial involvement in neurological disorders does not establish SS-31 as an effective neurological treatment.
Why One Mechanism Cannot Explain Every Disease
Different diseases involve distinct causes, affected tissues and biological pathways.
Even when mitochondrial dysfunction is present, it may be a cause, consequence or associated feature of disease.
What Research Questions Remain?
Important questions include the contribution of different membrane interactions, the relationship between target engagement and clinical outcomes, long-term effects in different populations and the ability of experimental biomarkers to predict meaningful benefit.
The Main Evidence Boundary
Elamipretide has an approved US indication for a specific rare disease. SS-31 peptide research
That approval does not validate broader anti-ageing, recovery or performance claims.
SS-31 Research: Evidence Strength by Application
| Research area | Evidence available | Scientific interpretation |
|---|---|---|
| Cardiolipin interaction | Biophysical and biochemical studies | Strong experimental support |
| Membrane electrostatics | Model and mitochondrial membrane experiments | Changes in surface properties demonstrated |
| Cristae organisation | Preclinical studies | Context-dependent structural effects |
| Cytochrome c behaviour | Biochemical and preclinical research | Mechanistic effects proposed |
| Oxidative phosphorylation | Cell and animal studies | Functional changes reported in selected models |
| Mitochondrial protein interactions | Cross-linking and mass spectrometry | Multiple associations identified |
| Barth syndrome | Human clinical development and FDA accelerated approval | Specific approved indication |
| General mitochondrial myopathies | Clinical research | No equivalent broad approval established here |
| Healthy athletic performance | Insufficient clinical evidence | Benefit not established |
| Human anti-ageing effects | Insufficient clinical evidence | Benefit not established |
SS-31 Analytical Testing and Laboratory Quality
Reliable SS-31 research depends on precise chemical identification.
The sequence contains unusual structural features that require attention during analytical characterisation.
Confirming the D-Amino Acid
SS-31 contains D-arginine.
A mass measurement alone may not distinguish a D-amino acid from its L-enantiomer.
Where stereochemical identity is important, suitable analytical methods are necessary. SS-31 peptide research
Confirming the Modified Tyrosine
The Dmt residue is not identical to ordinary tyrosine.
Correct identification of this modification is important for establishing molecular identity.
C-Terminal Amidation
SS-31 contains a C-terminal amide.
This feature should be included in the declared sequence and identity specifications.
HPLC Purity
High-performance liquid chromatography can provide information about chromatographic purity.
A main-peak area percentage does not independently establish absolute peptide content or all structural features.
LC-MS Analysis
Liquid chromatography–mass spectrometry can support molecular identity assessment and characterisation of certain impurities.
However, complementary methods may be required for stereochemical verification. SS-31 peptide research
Related Impurities
Peptide synthesis can produce sequence-related impurities.
Depending on the manufacturing process, these may include truncated sequences, altered residues or other related substances.
Peptide Content
Nominal vial mass should be distinguished from analytically determined active peptide content.
Counterions, water and other constituents may contribute to total sample mass.
Stability Testing
Stability depends on the specific chemical form and formulation.
Storage conditions should be based on suitable product-specific data rather than generic assumptions.
Batch Documentation
A meaningful Certificate of Analysis should identify the material, batch, methods and reported results.
Sterility and Endotoxins
Peptide identity and chromatographic purity do not establish sterility or endotoxin status. SS-31 peptide research
These are separate quality attributes. SS-31 peptide research
Pharmaceutical Equivalence
Even extensive analytical testing of a research material does not automatically make it equivalent to an FDA-approved drug product.
Pharmaceutical equivalence involves additional manufacturing, formulation and regulatory requirements.
Worked Example: Comparing Two SS-31 Research Documentation Packages
Consider two fictional materials labelled SS-31.
Both suppliers report a chromatographic purity of 99%.
| Verification item | Sample A | Sample B |
|---|---|---|
| Declared sequence | D-Arg–Dmt–Lys–Phe–NH₂ | SS-31 |
| Batch-specific HPLC | Available | Available |
| Mass spectrometry | Available | Not supplied |
| D-arginine configuration documented | Yes | Not specified |
| Dmt modification documented | Yes | Not specified |
| C-terminal amidation documented | Yes | Not specified |
| Absolute peptide content | Reported | Not supplied |
| Batch identification | Present | Present |
This is a hypothetical example for analytical education, not a comparison of actual suppliers.
Are the Materials Proven Equivalent?
No.
The same reported HPLC purity percentage does not establish that both samples contain the intended stereochemical and modified peptide structure. SS-31 peptide research
Which Documentation Is More Informative?
Sample A provides more information relevant to the molecular identity of SS-31.
However, the reliability of its claims still depends on the actual methods and results.
Why Is This Particularly Important for SS-31?
SS-31 contains D-arginine, a modified tyrosine and a C-terminal amide.
These features are relevant to the intended molecular structure.
What Is the Practical Lesson?
Researchers should assess whether the analytical evidence establishes the specific compound required for their experiment, rather than relying on a generic purity percentage.
SS-31 Compared With MOTS-c and Other Research Peptides
SS-31 is often grouped with other compounds associated with mitochondrial research.
However, their origins and proposed mechanisms differ. SS-31 peptide research
| Compound | Molecular identity | Research distinction |
|---|---|---|
| SS-31 / elamipretide | Synthetic modified tetrapeptide | Cardiolipin and mitochondrial membrane interactions |
| MOTS-c | Mitochondrial DNA-encoded 16-residue peptide | Metabolic stress and AMPK-related signalling |
| Humanin | Mitochondrial-associated peptide | Cell-survival and stress-related pathways |
| GHK-Cu | Copper-binding tripeptide complex | Metal coordination and extracellular matrix research |
These compounds should not be treated as interchangeable.
Evidence concerning one mitochondrial peptide does not establish the effects of another.
Similarly, a clinical approval for elamipretide does not confer regulatory approval on MOTS-c, Humanin or unrelated research compounds. SS-31 peptide research
Related Axion Peptide Lab Research Guides
Peptide Structure–Activity Relationships
Peptide Certificate of Analysis
Confirm these planned internal article URLs are published before adding them as live links.
SS-31 Research Materials at Axion Peptide Lab
Axion Peptide Lab provides information and a catalogue relevant to laboratory peptide research.
Researchers evaluating SS-31 should consult current product specifications and available batch documentation.
What Should Laboratories Verify?
Relevant attributes include the intended modified sequence, stereochemistry, chemical form, nominal content and appropriate identity testing. SS-31 peptide research
Does a High Purity Percentage Establish SS-31 Identity?
No.
Chromatographic purity alone cannot establish all structural attributes, particularly stereochemical identity.
Does FDA Approval Apply to Research Vials?
No.
FDA approval applies to the specified pharmaceutical product under its approved conditions.
Independently supplied research materials are not interchangeable with Forzinity.
Research-Only Distinction
Research materials must not be represented as approved treatments or substitutes for prescribed medicines.
Frequently Asked Questions About SS-31 Peptide Research
1. What is SS-31 peptide research?
SS-31 peptide research examines the synthetic tetrapeptide elamipretide, particularly its interactions with cardiolipin, mitochondrial membranes and cellular energy-related processes. SS-31 peptide research
2. Is SS-31 the same as elamipretide?
Yes. SS-31 and elamipretide generally refer to the same active peptide in scientific literature, although independently supplied research materials are not equivalent to an approved pharmaceutical formulation.
3. What is the SS-31 amino acid sequence?
The commonly reported sequence is D-Arg–Dmt–Lys–Phe–NH₂, where Dmt represents 2′,6′-dimethyltyrosine.
4. What is cardiolipin?
Cardiolipin is a phospholipid concentrated in the inner mitochondrial membrane. It contributes to membrane organisation and interactions with respiratory-chain proteins.
5. How does SS-31 interact with mitochondria?
Experimental studies show that SS-31 associates with cardiolipin-containing membranes and can alter lipid packing and membrane surface electrostatics.
6. Does SS-31 increase ATP production?
Selected preclinical studies report changes in mitochondrial respiration and ATP-related measurements. The effects depend on the model and do not establish general energy-enhancing benefits in healthy humans.
7. Is SS-31 FDA-approved?
The pharmaceutical product Forzinity (elamipretide) received FDA accelerated approval in September 2025 to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. This does not apply to independently supplied research peptides.
8. Has SS-31 been tested in humans?
Yes. Elamipretide has undergone human clinical studies, including a clinical development programme for Barth syndrome. The evidence varies by condition and outcome.
9. Is SS-31 proven to reverse ageing?
No. There is insufficient clinical evidence establishing SS-31 as a treatment that reverses normal human ageing.
10. How can laboratories verify SS-31 identity?
Relevant methods may include HPLC, LC-MS and complementary testing appropriate for the modified sequence, stereochemistry and chemical form.
Conclusion: What SS-31 Peptide Research Establishes
SS-31 peptide research has contributed important findings about the relationship between mitochondrial membrane chemistry and cellular energy-related processes.
The interaction between SS-31 and cardiolipin is supported by biochemical and biophysical evidence.
Experimental studies have also reported changes in membrane organisation, surface electrostatics, oxidative stress-related measurements and mitochondrial function.
The peptide has progressed into clinical development, culminating in the FDA’s September 2025 accelerated approval of elamipretide for a specific Barth syndrome indication.
That milestone is scientifically important, but its scope must be interpreted accurately.
It does not establish SS-31 as a general anti-ageing compound, an athletic performance enhancer or an approved treatment for every condition involving mitochondrial dysfunction.
The most useful scientific interpretation distinguishes established membrane interactions, preclinical observations and disease-specific clinical evidence.
For laboratories, accurate verification of the modified peptide sequence, stereochemistry and batch characteristics remains essential.
SS-31 is a significant example of cardiolipin-targeted peptide research, with a defined pharmaceutical application and many additional scientific questions still under investigation.
Scientific References
- Szeto HH. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology.
https://doi.org/10.1111/bph.12461 - Mitchell W, Ng EA, Tamucci JD, et al. (2020). The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action.
https://pubmed.ncbi.nlm.nih.gov/32273339/ - Mitochondrial Protein Interaction Landscape of SS-31. (2020). Research using cross-linking mass spectrometry to characterise mitochondrial protein interactions.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/ - United States Food and Drug Administration. (2025). FDA Grants Accelerated Approval to First Treatment for Barth Syndrome.
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome - United States Food and Drug Administration. (2025). Drug Trials Snapshots: Forzinity.
https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity - Shirley M. (2026). Elamipretide: First Approval. Drugs.
https://doi.org/10.1007/s40265-025-02269-8 - United States Food and Drug Administration. (2024). Cardiovascular and Renal Drugs Advisory Committee briefing materials concerning elamipretide for Barth syndrome.
https://www.fda.gov/media/182554/download - PubMed. SS-31 and elamipretide biomedical literature.
https://pubmed.ncbi.nlm.nih.gov/?term=SS-31+elamipretide
These sources support the scientific and regulatory discussion. They do not verify the identity, quality or pharmaceutical equivalence of independently supplied research materials.
Research-use notice: This article is provided for scientific education and legitimate laboratory research. Independently supplied SS-31 research materials are not approved pharmaceutical products and must not be represented as substitutes for Forzinity or any other prescribed medicine. This article does not provide medical advice or administration guidance.